A convenient treatment option for Thromboembolic Events

Zent2U would like to announce to all our B2B business partners that the Rivaroxaban Oral Suspension dossier is ready and we are now able to offer the product for out-licensing in selected markets in Europe on an exclusive or semi-exclusive base. The dossier can also be adjusted to markets outside Europe based on request. ✍🏼

For more information and to discover the benefits of Rivaroxaban Oral Suspension please contact Tomas Pilarcik, Rahul Padhye, Clara Vitaller Baguena or Nina Fuentes de Tienda.

#thrombosis #b2b #zent2u #outlicensing